期刊
LANCET DIABETES & ENDOCRINOLOGY
卷 5, 期 11, 页码 908-923出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S2213-8587(17)30184-5
关键词
-
资金
- Amgen
- Alexion
- AstraZeneca
- Lily
- D3 Biomedical Science Institutes
- GSK Nutrition
- Immunodiagnostic Systems
- Roche
- Medical Research Council [MR/P020941/1, MR/K006312/1] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0513-10073] Funding Source: researchfish
- MRC [MR/K006312/1, MR/P020941/1] Funding Source: UKRI
Bone turnover comprises two processes: the removal of old bone (resorption) and the laying down of new bone (formation). N-terminal propeptide of type I procollagen (PINP) and C-telopeptide of type I collagen (CTX-I) are markers of bone formation and resorption, respectively, that are recommended for clinical use. Bone turnover markers can be measured on several occasions in one individual with good precision. However, these markers are subject to several sources of variability, including feeding (resorption decreases) and recent fracture (all markers increase for several months). Bone turnover markers are not used for diagnosis of osteoporosis and do not improve prediction of bone loss or fracture within an individual. In untreated women, very high bone turnover marker concentrations suggest secondary causes of high bone turnover (eg, bone metastases or multiple myeloma). In people with osteoporosis, bone turnover markers might be useful to assess the response to anabolic and antiresorptive therapies, to assess compliance to therapy, or to indicate possible secondary osteoporosis. Much remains to be learnt about how bone turnover markers can be used to monitor the effect of stopping bisphosphonate therapy (eg, to identify a threshold above which restarting therapy should be considered). More studies are needed to investigate the use of bone turnover markers for assessment of the bone safety of new medications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据